Another baby and another cutaneous lesion--and more on efficient recognition and management

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.

Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.

A supplemental Biologics License Application has been accepted by the FDA for treating adolescents and adults with chronic spontaneous urticaria.

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.

A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.